Display options
Cite
McLeod DG. The effective management of biochemical recurrence in patients with prostate cancer. Rev Urol. 2005;7:S29-36
McLeod, D. G. (2005). The effective management of biochemical recurrence in patients with prostate cancer. Reviews in urology, 7S29-36.
McLeod, David G. "The effective management of biochemical recurrence in patients with prostate cancer." Reviews in urology vol. 7 (2005): S29-36.
McLeod DG. The effective management of biochemical recurrence in patients with prostate cancer. Rev Urol. 2005;7:S29-36. PMID: 16985881; PMCID: PMC1477616.
Copy Download .nbib Format: NLM
Share it on

Rev Urol. 2005;7:S29-36.

The effective management of biochemical recurrence in patients with prostate cancer.

Reviews in urology

David G McLeod

PMID: 16985881 PMCID: PMC1477616

Abstract

Prostate-specific antigen (PSA) testing has become the primary method of monitoring patients following definitive therapy for clinically localized prostate cancer. After surgery, an immediate detectable rise in PSA is correlated with subsequent local recurrence and/or metastasis. Following radiation therapy, biochemical failure is defined as 3 consecutive rises in PSA above the nadir. Treatment of postoperative or postradiation PSA recurrence involves several modalities, including luteinizing hormone-releasing hormone agonists. Although studies have demonstrated the advantages of early hormone therapy, they have not addressed at what PSA level treatment should begin. A better understanding of PSA's kinetics will lead to a sense of when to begin treatment and when watchful waiting is the more appropriate course.

References

  1. J Urol. 1994 Nov;152(5 Pt 1):1515-9 - PubMed
  2. Br J Urol. 1997 Feb;79(2):235-46 - PubMed
  3. Urol Clin North Am. 1997 May;24(2):395-406 - PubMed
  4. J Clin Oncol. 2003 Jan 15;21(2):383-91 - PubMed
  5. J Urol. 2001 Apr;165(4):1146-51 - PubMed
  6. J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7 - PubMed
  7. Urol Int. 2004;73(2):117-22 - PubMed
  8. Urology. 2000 Aug 1;56(2):289-94 - PubMed
  9. Am J Surg Pathol. 2000 Apr;24(4):579-86 - PubMed
  10. J Clin Invest. 1987 Aug;80(2):281-5 - PubMed
  11. Semin Urol Oncol. 2000 May;18(2):160-5 - PubMed
  12. N Engl J Med. 1991 Apr 25;324(17):1156-61 - PubMed
  13. Clin Prostate Cancer. 2002 Dec;1(3):163-71 - PubMed
  14. J Urol. 1993 Mar;149(3):516-8 - PubMed
  15. Br J Cancer. 1997;75(11):1646-51 - PubMed
  16. J Urol. 2005 Feb;173(2):373-9 - PubMed
  17. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):845-9 - PubMed
  18. J Clin Pathol. 2005 Jan;58(1):69-71 - PubMed
  19. Oncology (Williston Park). 1998 Jan;12(1):33-9; discussion 39, 43-4, 47 - PubMed
  20. Urol Clin North Am. 2001 Aug;28(3):555-65 - PubMed
  21. BJU Int. 2005 Jan;95(1):163-9 - PubMed
  22. J Urol. 2000 Apr;163(4):1085-9 - PubMed
  23. Appl Immunohistochem Mol Morphol. 2000 Jun;8(2):158-61 - PubMed
  24. Semin Radiat Oncol. 2003 Apr;13(2):166-74 - PubMed
  25. J Urol. 2004 Mar;171(3):1141-7 - PubMed
  26. Endocr Rev. 2001 Apr;22(2):184-204 - PubMed
  27. Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):10-8 - PubMed
  28. J Urol. 1988 Apr;139(4):766-72 - PubMed
  29. JAMA. 1999 May 5;281(17):1591-7 - PubMed
  30. Int J Clin Pract. 2004 Apr;58(4):382-90 - PubMed
  31. N Engl J Med. 2004 Jul 8;351(2):125-35 - PubMed
  32. Oncology (Williston Park). 2004 May;18(5):595-604; discussion 605, 609 - PubMed
  33. J Urol. 2000 Jun;163(6):1632-42 - PubMed
  34. J Urol. 1989 Apr;141(4):873-9 - PubMed
  35. N Engl J Med. 1999 Dec 9;341(24):1781-8 - PubMed
  36. J Androl. 1999 May-Jun;20(3):348-55 - PubMed

Publication Types